Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma
|
|
- Grant Paul
- 5 years ago
- Views:
Transcription
1 Anatomic Pathology / HER-2/NEU IN BREAST CARCINOMA Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma Russell Vang, MD, 1 Linda D. Cooley, MD, 1 Wilbur R. Harrison, MS, 1 Tommy Reese, 2 and Jacki Abrams, MD 1,2 Key Words: HER-2/neu; C-erbB2; Immunohistochemistry; FISH; Fluorescence in situ hybridization; Breast carcinoma Abstract Numerous methods exist for HER-2/neu assessment; however, technical and interpretive standardization is virtually absent. We evaluated 2 commercially available antibodies on routinely fixed paraffin-embedded tissue sections to establish our own guidelines. Thirty-three cases of infiltrating breast carcinoma were evaluated simultaneously with monoclonal and polyclonal antibodies. Only membranous staining, no matter how focal, was considered positive. An additional 32 tumors were studied subsequently using only the polyclonal antibody. Of all carcinomas, 13.0% showed immunohistochemical evidence of HER-2/neu overexpression. High-grade tumors were more often positive. There was no HER-2/neu gene expression in the benign epithelium that generally was present in the tissue section or in any of the well-differentiated tumors tested. The polyclonal antibody proved more sensitive than the monoclonal antibody. While true cytoplasmic staining was present occasionally, it did not create substantial difficulty in interpretation. The polyclonal antibody cost substantially less than the monoclonal antibody. Fluorescence in situ hybridization assay for HER-2/neu gene amplification performed on 32 of 65 cases showed concordant results in 31 cases. The immunohistochemical assay for HER-2/neu gene overexpression, using our methods, is accurate, economic, and easily integrated into the laboratory. Neu is a proto-oncogene that encodes a 185-kd protein that shares homology with epidermal growth factor receptor. Cloned from complementary DNA, it is referred to as HER-2, and cloned from genomic DNA, it is referred to as c-erbb-2; the 2 designations are used interchangeably in the literature. One copy of the gene resides on each chromosome 17 at band q21 and is thought to have a role in cell motility. The gene is amplified and the protein overexpressed in carcinomas, particularly those of the breast. The protein has 3 components, an external domain, a transmembranous portion, and an internal domain. 1 The prognostic significance of HER-2/neu amplification in breast cancer has been the subject of debate for years. Ali et al 2 concluded that c-erbb-2 amplification had no independent prognostic value compared with traditional factors, while others have demonstrated the prognostic value of HER-2/neu amplification in metastatic disease. 3 More recent studies show that HER-2/neu overexpression has therapeutic implications in infiltrating breast cancer. Trastuzumab (Herceptin), a monoclonal antibody against the p185 HER-2/neu protein (recently approved by the US Food and Drug Administration [FDA]), has therapeutic efficacy in HER-2/neu-overexpressing tumors. 4 Tumor responsiveness to tamoxifen and traditional chemotherapy also is influenced by HER-2/neu overexpression Laboratory methods for assessing HER-2/neu amplification or HER-2/neu overexpression include Southern, Northern, and Western blot techniques; immunohistochemistry, and, recently, fluorescence in situ hybridization (FISH). However, there is no clear standardization for HER-2/neu testing. The recently FDA-approved HercepTest (DAKO, Carpinteria, CA) is a move toward standardization. The goal of our study was to develop an American Society of Clinical Pathologists Am J Clin Pathol 2000;113:
2 Vang et al / HER-2/NEU IN BREAST CARCINOMA accurate cost-effective assay that is easily incorporated into the surgical pathology laboratory. Materials and Methods A total of 216 breast tumors were examined for HER- 2/neu protein overexpression by immunohistochemical methods. Initially, 33 intermediate- or high-grade (Elston- Ellis method 13 ) infiltrating breast carcinomas were assessed. Formalin-fixed paraffin-embedded tissue was evaluated using 2 commercially available antibodies, PC-11 (polyclonal, 1:3000, Novocastra, Burlingame, CA) and TAB-250 (monoclonal, 1:10, Zymed, South San Francisco, CA). When the monoclonal antibody was depleted, 32 additional consecutively accessioned tumors (all grades) were evaluated by the polyclonal antibody alone. After evaluation of the results from the first 65 tumors, 14 we studied an additional 151 tumors using the polyclonal antibody with correlation of results with histologic type and grade. The avidin-biotin-complex method was used, and all reactions were performed at room temperature. 15 Briefly, tissue sections were deparaffinized and hydrated with distilled water. Slides were quenched with 30% methanolic hydrogen peroxide for 5 minutes and then placed in phosphate-buffered saline (PBS), ph 7.6. Blocking solution was applied for 20 minutes, followed by incubation with the primary antibody for 1 hour. Slides received a 5-minute PBS rinse before application of a biotinylated secondary antibody for 30 minutes and a second 5-minute PBS rinse. Vectastain ABC working reagent (Vector Laboratories, Burlingame, CA) was added for 30 minutes followed by a 5-minute PBS rinse. Slides were developed with 3,3 diaminobenzidine for 2 to 5 minutes, rinsed in distilled water for 5 minutes, counterstained with Richard-Allen hematoxylin for 45 seconds, and rinsed again with distilled water. After a 5-second dip in 1% acid alcohol, slides were rinsed in distilled water, placed in Richard-Allen bluing reagent for 5 seconds, rinsed with tap water, and dehydrated, and coverglasses were applied. Comedo ductal carcinoma in situ was used as a positive control. Dilutions were adjusted to minimize background staining and maximize membranous staining present in the comedo ductal carcinoma in situ. Although neither antibody manufacturer recommended antigen retrieval, heat-induced epitope retrieval using citrate buffer, ph 6.0, or EDTA (1- mmol/l concentration, ph 8.0), with microwaving, was tried but neither seemed to enhance staining of the control sections. For test cases, HER-2/neu protein overexpression was considered present when any percentage of the infiltrating component showed definitive membranous staining. 16 Thirty-two of the first 65 tumors were studied using the FDA-approved FISH assay (ONCOR, Gaithersburg, MD) to detect HER-2/neu gene amplification. This was done in a blinded fashion to validate the accuracy and sensitivity of the immunohistochemical results. Three groups of tumors were evaluated: 9 high-grade carcinomas (8 poorly and 1 moderately differentiated) that were positive by immunohistochemistry, 11 high-grade carcinomas (8 poorly and 3 moderately differentiated) that were negative by immunohistochemistry, and 12 well-differentiated carcinomas that were negative by immunohistochemistry. Nine of the negative cases selected for FISH showed cytoplasmic staining that was not considered background. Amplification of the HER-2/neu gene was considered present whenever an average of more than 4 signals was counted per nucleus. However, in selected tumors, a chromosome 17 centromeric DNA probe was hybridized simultaneously with the HER-2 probe to determine chromosome 17 copy number and distinguish true amplification from chromosome aneuploidy Image 1. Results Membranous staining was interpreted as positive for overexpression of the HER-2/neu protein product. While the majority of tumors showed staining in more than 50% of the infiltrating component, focal staining also was interpreted as positive Image 2. The overall quality of staining was similar between the polyclonal and monoclonal anti- Image 1 HER-2/neu gene amplification by fluorescence in situ hybridization; blue nuclei show 2 red chromosome 17 signals and many green HER-2/neu signals ( 1,000). 670 Am J Clin Pathol 2000;113: American Society of Clinical Pathologists
3 Anatomic Pathology / ORIGINAL ARTICLE Image 2 Membranous pattern of HER-2/neu protein overexpression ( 200). bodies. Some tumors showed nonbackground cytoplasmic staining, but this alone was not considered positive Image 3. No membranous staining was noted in the nonneoplastic epithelium in any tumor. In the 33 high-grade tumors used for the initial antibody study, a higher percentage of tumors with overexpression was detected with the polyclonal antibody (10/33, [30%]) than with the monoclonal antibody (4/33 [12%]). At the final working concentration, the polyclonal antibody cost $0.50/mL, while the monoclonal antibody cost $30.00/mL. When using only the polyclonal antibody for study of the next 32 consecutively accessioned tumors, none of the welldifferentiated tumors showed overexpression. In these 65 tumors, overexpression was detected in 2 (15%) of 13 moderately differentiated tumors and 9 (23%) of 39 poorly differentiated tumors. In the 32 tumors selected for FISH assay Table 1, several showed 4 to 10 HER-2/neu signals. Simultaneous assay with chromosome 17 and HER-2/neu probes showed only 1 tumor to have discordant immunohistochemical and FISH results. Two tumors were aneuploid with multiple copies of chromosome 17. One tumor positive by FISH and negative by immunohistochemical testing showed focal immunoreactivity in additional tissue sections studied with immunohistochemistry. Because there was an admixture of the in situ and infiltrating components of this tumor, localization of the immunoreactivity was difficult. None of the tumors that showed only cytoplasmic staining were positive by FISH. Correlation between immunohistochemical and FISH results was 97%. Twenty-two cases, in which there Image 3 HER-2/neu protein overexpression by immunohistochemistry. Nonspecific cytoplasmic and true membranous staining are shown ( 400). was no amplification by FISH, were subsequently subjected to heat-induced epitope retrieval before the aforementioned immunohistochemical procedure. There was increased cytoplasmic staining, but no additional positive cases with membranous staining were detected. We assayed 216 consecutive breast tumors, 33 with both monoclonal and polyclonal antibodies and 183 with polyclonal antibody alone. The overall incidence of HER- 2/neu overexpression in the present study was 13.0% (28/216). Breakdown by histologic grade and type is shown in Table 2. Discussion Amplification of the HER-2/neu gene or overexpression of the protein has been shown to have variable prognostic significance for women with infiltrating breast carcinoma. 2,3,17,18 Breast carcinomas that overexpress HER-2/neu are unresponsive to hormonal therapy, eg, tamoxifen, and require a more intense regimen of traditional chemotherapy for effective treatment A new FDA-approved drug, trastuzumab, is specific for treatment of breast tumors with overexpression of HER-2/neu. 4,8 Because of this new focus on the treatment of women with breast cancer, pathologists and oncologists need an accurate and cost-effective test for HER-2/neu gene expression to determine the most appropriate therapy for individual patients. Earlier methods for detecting HER-2/neu overexpression were Southern, Northern, and Western blot techniques. American Society of Clinical Pathologists Am J Clin Pathol 2000;113:
4 Vang et al / HER-2/NEU IN BREAST CARCINOMA Table 1 HER-2/neu Results by Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Interpretation Case No. IHC FISH Chromosome 17* Copy No. HER-2/neu Copy No. 1 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND > ND > ND > ND > > ND, not done; +, positive;, negative. * Chromosome 17 probe used selectively. Table 2 Type, Grade, and HER-2/neu Status of 216 Tumors * Total HER-2/neu Positive Histologic type Ductal 185 (85.6) 27 (14.6) Mixed ductal/lobular 10 (4.6) 1 (10) Lobular, classic 8 (3.7) 0 (0) Tubular 4 (1.9) 0 (0) Mucinous 4 (1.9) 0 (0) Metaplastic (sarcomatoid) 2 (0.9) 0 (0) Cribriform 1 (0.5) 0 (0) Micropapillary 1 (0.5) 0 (0) Papillary 1 (0.5) 0 (0) Histologic grade Well-differentiated 56 (26.2) 0 (0) Moderately differentiated 66 (30.8) 4 (6) Poorly differentiated 92 (43.0) 23 (25) Nuclear grade Low 28 (13) 0 (0) Intermediate 96 (44.4) 6 (6) High 92 (42.6) 22 (24) * Data are given as number (percentage). Insufficient tumor material to assign histologic grade in 2 tumors. Limitations of these molecular techniques are insensitivity to low levels of amplification owing to the dilutional effect of nonneoplastic tissue within a given sample and an inability to distinguish overexpression of an in situ from an infiltrating carcinoma. Disadvantages are the required technical expertise and expense. Conversely, immunohistochemical methods offer the advantage of direct visualization of the cell type with protein overexpression. Immunohistochemistry for HER-2/neu expression, however, has yet to be standardized. Published frequencies of HER-2/neu overexpression in breast cancers range from 14% to 89%. 19,20 The recent development and FDA approval of the HercepTest was the first attempt at standardization of the immunohistochemical method. The HercepTest uses a polyclonal antibody (DAKO), and interpretation of the assay is based on patient response to the drug Herceptin determined in the Herceptin Phase 2 clinical trial. 4,21 Problems with this test are addressed elsewhere. 22,23 While the specificity of the DAKO antibody was well documented by multiple sophisticated molecular methods, 24 the criteria for interpretation of overexpression were based on a subjective scoring system defined primarily by intensity of membranous staining. 4 In our experience, staining intensity in immunohistochemistry assays depends on a number 672 Am J Clin Pathol 2000;113: American Society of Clinical Pathologists
5 Anatomic Pathology / ORIGINAL ARTICLE of factors and can be extremely variable. The accuracy is reliable only when tissues are fixed, processed, and assayed together, thus controlling for reagent variability and other conditions that may alter staining intensity. The HercepTest, while FDA approved, has not been shown to be superior to other immunohistochemical methods and is substantially more expensive for the laboratory at $40 per test (kit price, $1,225). FISH is a method for direct visualization of HER-2/neu gene amplification. Results correlate with immunohistochemistry and other techniques. 25,26 Ratcliffe et al 27 concluded that FISH was no more sensitive than immunohistochemistry on formalin-fixed tissue. They and others 26 were unable to demonstrate HER-2/neu gene amplification by FISH in the absence of HER-2/neu protein overexpression by immunohistochemistry. In our study, we used FISH to evaluate the accuracy and sensitivity of our immunohistochemical methods. The overall incidence of HER-2/neu protein overexpression by immunohistochemistry in the 216 tumors we have studied thus far is 13.0%. This is substantially lower than the 25% to 30% rate of some studies. 3,20,27-29 Of all breast cancers in the present study, the only histologic type that seems to show overexpression is infiltrating ductal carcinoma. If we eliminate the better prognosis special type tumors, well-differentiated infiltrating ductal carcinomas, and classic pure infiltrating lobular carcinomas, our incidence of overexpression (17%) is comparable to that of other studies. 16,17,30 As newer antibodies are developed, sensitivity and specificity for the detection of HER-2/neu overexpression by this technique undoubtedly will improve, as it has in the immunohistochemical determination of estrogen and progesterone receptors. 31 The HER-2/neu oncoprotein is a transmembrane protein. Therefore, the immunohistochemical staining of the HER-2/neu protein is present in the cell membrane. Staining of the membrane represents true protein overexpression, and any percentage of positive cells is considered important. Cytoplasmic staining, when present, should never be interpreted as positive. Positive and negative control samples must be processed simultaneously with the unknown patient sample. Normal nonneoplastic breast epithelium, when present, should serve as an internal negative control. 32 In the present study, we compared 2 commercially available antibodies to determine which was better for immunohistochemical assessment of the HER-2/neu protein overexpression. We validated the immunohistochemical results by FISH and showed excellent correlation. We concluded the following: (1) While the FISH assay is accurate, the cost of the FISH DNA probe and the special expertise required to perform FISH analysis makes immunohistochemistry the most cost-effective method currently available for assessing HER-2/neu. (2) The polyclonal antibody by Novocastra is superior to the monoclonal antibody by Zymed with respect to sensitivity and cost. (3) HER-2/neu overexpression, determined by immunohistochemistry, correlates with tumor grade. (4) Provided that adequate internal and external controls are used and interpretation is made from cell membrane staining, immunohistochemistry is one of the most accurate and reliable methods available. From 1 The University of Texas Medical School and 2 St Luke s Episcopal Hospital, Houston, TX. Presented in part as an abstract poster at the March 1999 United States and Canadian Academy of Pathology Meeting in San Francisco, CA. Address reprint requests to Dr Abrams: St Luke s Episcopal Hospital, Dept of Pathology, 6720 Bertner St, MC4-265, Houston, TX Acknowledgments: We thank Anwar Farhood, MD, Houston, TX, and Hector Battifora, MD, Cypress, CA, for their critical review and helpful comments, and Eric Bernicker, MD, our clinical oncology colleague who inspired this study. References 1. De Potter CR, Schelfhout A-M. The neu-protein and breast cancer. Virchows Arch. 1995;426: Ali IU, Campbell G, Libereau R, et al. Lack of evidence for the prognostic significance of c-erbb-2 amplification in human breast carcinoma. Oncogene Res. 1988;3: Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244: Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16: Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-her2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58: Pegram MD, Pietras RJ, Slamon DJ. Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells. Proc Am Assoc Cancer Res. 1992;33:442. Abstract Muss HB, Thor AD, Berry DA, et al. c-erbb-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Med. 1994;330: Ravdin PM, Green S, Albain KS, et al. Initial report of the SWOG biological correlative study of c-erbb-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone. Proc Am Soc Clin Oncol. 1998;17:97a. Abstract Bianco AR, De Laurentis M, Carlomagno C, et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erbb-b2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol. 1998;17:97a. Abstract 373. American Society of Clinical Pathologists Am J Clin Pathol 2000;113:
6 Vang et al / HER-2/NEU IN BREAST CARCINOMA 10. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994;81: Carlomagno C, Perrone F, Gallo C, et al. c-erbb2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14: Wright C, Nicholson S, Angus B, et al. Relationship between c-erbb-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65: Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19: Vang R, Abrams J. Determining HER2/neu expression in breast carcinoma. Mod Pathol. 1999;12:194A. Abstract Bratthauer GL. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods. Methods Mol Biol. 1999;115: McCann AH, Dervan PA, O Regan M, et al. Prognostic significance of c-erbb-2 and estrogen receptor status in human breast cancer. Cancer Res. 1991;51: Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10: Zhou D-J, Ahuja H, Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-erbb-2 amplification does not correlate with recurrence of disease. Oncogene. 1989;4: Midulla C, Giovagnoli MR, Valli C, et al. Correlation between ploidy status, ERB-B2 and p53 immunohistochemical expression in primary breast carcinoma. Anal Quant Cytol Histol. 1995;17: Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994;173: Cobleigh MA, Vogel CL, Tripathy D. Efficacy and safety of Herceptin (humanized anti-her-2 antibody) as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol. 1998;17:97a. Abstract Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration approved scoring system. J Clin Oncol. 1999;17: Roche PC, Ingle JN. Increased HER-2 with US Food and Drug Administration approved antibody. J Clin Oncol. 1999;17: Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 1990;50: Kallioniemi O-P, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992;89: Pauletti G, Godolphin W, Press MF, et al. Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13: Ratcliffe N, Wells W, Wheeler K, et al. The combination of in-situ hybridization and immunohistochemical analysis: an evaluation of HER-2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol. 1997;10: Horiguchi J, Iino Y, Takei H, et al. Immunohistochemical study on the expression of c-erbb-2 oncoprotein in breast cancer. Oncology. 1994;51: Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbb-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol. 1992;23: Allred DG, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23: Allred DC, Harvey JM, Berardo, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11: Battifora H, Gaffey M, Esteban J, et al. Immunohistochemical assay of neu/c-erb-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol. 1991;4: Am J Clin Pathol 2000;113: American Society of Clinical Pathologists
HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationAssessment of Her-2/neu Overexpression in Primary Breast Cancers and Their Metastatic Lesions: An Immunohistochemical Study
Annals o f Clinical & Laboratory Science, vol. 30, no. 3, 2000 259 Assessment of Her-2/neu Overexpression in Primary Breast Cancers and Their Metastatic Lesions: An Immunohistochemical Study Shahla Masood
More informationT he HER2/neu type 1 tyrosine kinase growth factor
710 ORIGINAL ARTICLE HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationComparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer
Anatomic Pathology / HER-2 DETECTION BY CISH IN BREAST CANCER Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer Deepali Gupta, MD, 1
More informationComparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice
Anatomic Pathology / ASSESSMENT OF HER-2 STATUS Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice Michelle Dolan, MD, 1 and Dale Snover,
More informationKEY WORDS: Breast carcinoma, c-erbb2, Fluorescent. Mod Pathol 2001;14(11):
HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization Thomas A. Thomson, M.D., Malcolm M. Hayes,
More informationTITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.
AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School
More informationHER-2/neu Protein Expression in Breast Cancer Evaluated by Immunohistochemistry A Study of Interlaboratory Agreement
Anatomic Pathology / INTERLABORATORY AGREEMENT OF HER-2/NEU EXPRESSION BY IMMUNOHISTOCHEMISTRY HER-2/neu Protein Expression in Breast Cancer Evaluated by Immunohistochemistry A Study of Interlaboratory
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationHER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
Original article Annals of Oncology 13: 1398 1403, 2002 DOI: 10.1093/annonc/mdf217 HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
More informationThe HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Jeffrey S. Ross and Jonathan A.
The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Jeffrey S. Ross and Jonathan A. Fletcher The Oncologist 1998, 3:237-252. The online version of this
More informationEvaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters
Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters Mehdi Farzadnia, Naser TayyebiMeibodi, Fatemeh HomayiShandiz,
More informationImpact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification
Journal of Molecular Diagnostics, Vol. 5, No. 3, August 2003 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology Impact of Polysomy 17 on HER-2/neu Immunohistochemistry
More informationCase Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland
Pathology International 2008; 58: 322 326 doi:10.1111/j.1440-1827.2008.02231.x Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland Hidetaka Yamamoto, 1 Hideoki Uryu,
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS
ISPUB.COM The Internet Journal of Pathology Volume 13 Number 1 Learning Experience In Immunohistochemical Reporting Of Breast Cancer At A Rural Tertiary Hospital In India: A Comparison In Initial And Reviewed
More informationS Wang, M H Saboorian, E Frenkel, L Hynan, S T Gokaslan, R Ashfaq
374 Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9072, USA S Wang M H Saboorian R Ashfaq Department of Internal Medicine, University
More informationJournal of Breast Cancer
ORIGINAL ARTICLE Journal of Breast Cancer J Breast Cancer 2009 December; 12(4): 235-40 DOI: 10.4048/jbc.2009.12.4.235 Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationSymposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationT he HER-2 gene encodes a 185 kda transmembrane
611 ORIGINAL ARTICLE Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer H J Huang, P Neven, M Drijkoningen, R Paridaens,
More informationChinese Bulletin of Life Sciences. Over-expression of HER-2/neu and targeted therapy. CHEN Yu-ping
22 1 2010 1 Chinese Bulletin of Life Sciences Vol. 22, No. 1 Jan., 2010 1004-0374(2010)01-0069-05 HER-2/neu 100048 HER-2/neu HER- 2/neu 20%~30% P185HER2 P185HER2 (Herceptin) HER2/neu HER-2/neu P185HER2
More informationHER2/neu Evaluation of Breast Cancer in 2019
HER2/neu Evaluation of Breast Cancer in 2019 A.A. Sahin, M.D. Professor of Pathology and Translation Molecular Pathology Section Chief of Breast Pathology ERBB2 (HER2) Background 185-kDa membrane protein
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationEnhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy
Anatomic Pathology / HER-2 IMMUNOHISTOCHEMICAL SCORING RELIABILITY Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy Kenneth Bloom, MD, 1 and Douglas Harrington,
More informationConsiderable advances in the therapy of breast cancer
HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System Kelly C. Lear-Kaul, MD; Hye-Ryoung Yoon, MD; Bette K. Kleinschmidt-DeMasters, MD; Loris McGavran, PhD; Meenakshi Singh, MD Context.
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationHER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer
Hendrick van Vliet, 1662. Interior of the Nieuwe Kerk in Delft. From the collection of Dr. Gordon and Adele Gilbert of St.Petersburg, Florida. HER-2 as a Prognostic, Predictive, and Therapeutic Target
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationReceived 04 November 2008; Accepted in revision 09 January 2009; Available online 20 January 2009
Int J Clin Exp Pathol (2009) 2, 476-480 www.ijcep.com/ijcep811001 Original Article Immunohistochemical Detection of Estrogen and Progesterone Receptor and HER2 Expression in Breast Carcinomas: Comparison
More informationCell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-
Supplemental material and methods Reagents. Hydralazine was purchased from Sigma-Aldrich. Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC- 133, human thyroid medullary
More informationImmunohistochemical (IHC) HER-2/neu and Fluorescent- In Situ Hybridization (FISH) Gene Amplification of Breast Cancer in Indian Women
Comparison of IHC and FISH for HER-2/neu Status of Breast Cancer in Indian Women RESEARCH COMMUNICATION Immunohistochemical (IHC) HER-2/neu and Fluorescent- In Situ Hybridization (FISH) Gene Amplification
More informationImportance of confirming HER2 overexpression of recurrence lesion in breast cancer patients
Breast Cancer (2013) 20:336 341 DOI 10.1007/s12282-012-0341-6 ORIGINAL ARTICLE Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Rikiya Nakamura Naohito Yamamoto
More informationHypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients
Journal of BUON 17: 663-668, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor
More informationClinico-pathological significance of extra-nodal spread in special types of breast cancer
Cancer Biol Med 2014;11:116-122. doi: 10.7497/j.issn.2095-3941.2014.02.006 ORIGINAL ARTICLE Clinico-pathological significance of extra-nodal spread in special types of breast cancer Ecmel Isik Kaygusuz,
More informationc-erbb-2 overexpression and histologlical type of in situ and invasive breast carcinoma
16 J Clin Pathol 1992;45:16-20 Department of Histopathology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD J E Somerville L A Clarke J D Biggart Correspondence to: Dr J Somerville Accepted for publication
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationAssessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
More informationComparison of HER2/neu Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry
Anatomic Pathology / ASSESSMENT OF HER2/NEU STATUS Comparison of HER2/neu Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry Frances P. O Malley, MB, 1,2 Robert Parkes,
More informationTechnical Advance. Chromogenic in Situ Hybridization
American Journal of Pathology, Vol. 157, No. 5, November 2000 Copyright American Society for Investigative Pathology Technical Advance Chromogenic in Situ Hybridization A Practical Alternative for Fluorescence
More informationARTICLES. erbb-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
ARTICLES erbb-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer Ann D. Thor, Donald A. Berry, Daniel R. Budman, Hyman B. Muss, Timothy Kute, I. Craig Henderson, Maurice Barcos,
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationOn May 4 and 5, 2002, the College of American Pathologists
College of American Pathologists Conference Conference Summary, Strategic Science Symposium Her-2/neu Testing of Breast Cancer Patients in Clinical Practice Richard J. Zarbo, MD, DMD; M. Elizabeth H. Hammond,
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationHER2+ Breast Cancer Review of Biologic Relevance and Optimal Use of Diagnostic Tools
Anatomic Pathology / HER2: BIOLOGIC RELEVANCE AND DIAGNOSIS HER2+ Breast Cancer Review of Biologic Relevance and Optimal Use of Diagnostic Tools David G. Hicks, MD, 1 and Swati Kulkarni, MD 2 Key Words:
More informationWomen with axillary lymph node-negative breast carcinoma have
2516 A Combination of HER-2 Status and the St. Gallen Classification Provides Useful Information on Prognosis in Lymph Node-Negative Breast Carcinoma Jong-Mu Sun, M.D. 1 Wonshik Han, M.D. 2 Seock-Ah Im,
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationCME/SAM. Abstract. Anatomic Pathology / HER2/neu Results in Breast Cancer
Anatomic Pathology / HER2/neu Results in Breast Cancer Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2/neu Immunohistochemical and Fluorescence In Situ Hybridization Results in Breast
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationHER2 Testing of Multifocal Invasive Breast Carcinoma. Gillian C. Bethune, MD, J. Brendan Mullen, MD, and Martin C. Chang, MD, PhD
HER2 Testing of Multifocal Invasive Breast Carcinoma How Many Blocks Are Enough? Gillian C. Bethune, MD, J. Brendan Mullen, MD, and Martin C. Chang, MD, PhD From the Department of Pathology and Laboratory
More informationImmunohistochemical Evaluation of Necrotic Malignant Melanomas
Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast Version: Template Posting Date: January 2018 Includes requirements from the 2017 CAP Accreditation
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationRESEARCH ARTICLE. Wan Faiziah Wan Abdul Rahman 1 *, Mohd Hashairi Fauzi 2, Hasnan Jaafar 1. Abstract. Introduction
RESEARCH ARTICLE Expression of DNA Methylation Marker of Paired-Like Homeodomain Transcription Factor 2 and Growth Receptors in Invasive Ductal Carcinoma of the Breast Wan Faiziah Wan Abdul Rahman 1 *,
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationDepartment of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2
Hindawi Publishing Corporation Pathology Research International Volume 2012, Article ID 947041, 7 pages doi:10.1155/2012/947041 Clinical Study The Effect of Cold Ischemia Time and/or Formalin Fixation
More informationBreast cancer diagnostic solutions Deliver diagnostic confidence
Breast cancer diagnostic solutions Deliver diagnostic confidence 2 Breast cancer diagnostic solutions Roche Tissue Diagnostics is committed to improving outcomes in breast cancer Breast cancer...the most
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationA712(18)- Test slide, Breast cancer tissues with corresponding normal tissues
A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: No. of cases: 12 Tissue type: Breast cancer tissues with corresponding
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationFinal published version:
Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and postneoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience Mary Diane Kinsella, Emory University
More informationOverview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010
Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationPathologic Features of Breast Cancers in Women With Previous Benign Breast Disease
Anatomic Pathology / BREAST CANCERS AFTER BENIGN BIOPSY DIAGNOSES Pathologic Features of Breast Cancers in Women With Previous Benign Breast Disease Timothy W. Jacobs, MD, 1 Celia Byrne, PhD, 2 Graham
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2011 December; 14(4): 276-282 Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification
More informationThe role of p95her2 in trastuzumab resistance in breast cancer
JBUON 2016; 21(2): 382-389 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE The role of p95her2 in trastuzumab resistance in breast cancer Nuket
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationExpression of androgen receptors in primary breast cancer
Annals of Oncology 21: 488 492, 2010 doi:10.1093/annonc/mdp510 Published online 3 November 2009 Expression of androgen receptors in primary breast cancer S. Park 1, J. Koo 2, H. S. Park 1, J.-H. Kim 1,
More informationThe Expression of Basal Cytokeratins in Breast Cancers
Global Journal of Medical Research: C Microbiology and Pathology Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online
More informationTumour markers in breast carcinoma correlate with grade rather than with invasiveness
doi: 10.1054/ bjoc.2001.1995, available online at http://www.idealibrary.com on http://www.bjcancer.com Tumour markers in breast carcinoma correlate with grade rather than with invasiveness F Wärnberg
More informationAndrogen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations
Anatomic Pathology / ANDROGEN RECEPTOR IN BREAST CANCER Androgen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations S. Nicholas Agoff,
More informationHER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy
HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy Shigeya Kyoda 1, Satoki Kinoshita 2, Hiroshi Takeyama 1, Ken Uchida 2 and Toshiaki Morikawa 2 1 Department of Surgery, Jikei
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationIs adjuvant chemotherapy necessary for Luminal A-like breast cancer?
JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationFunctional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
Britsh Journal of Cancer (1996) 74, 802-806 $0 (g 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overepressing
More informationT he HER2 gene encodes a receptor tyrosine kinase that is
1069 ORIGINAL ARTICLE Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1 F J Fleming, E Myers, G Kelly, T B Crotty, E W McDermott, N J O
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationReviews in Clinical Medicine
Mashhad University of Medical Sciences (MUMS) Reviews in Clinical Medicine Clinical Research Development Center Ghaem Hospital Prognostic value of HER2/neu expression in patients with prostate cancer:
More informationEstrogen receptor (ER)
Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0%
More informationPotential Value of Hormone Receptor Assay in Carcinoma In Situ of Breast
Potential Value of Hormone Receptor Assay in Carcinoma In Situ of Breast ROBERT BARNES, M.D. AND SHAHLA MASOOD, M.D. The estrogen receptor (ER) expression of invasive breast cancer has been extensively
More informationBreast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens
Breast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens M. Shahid Siddiqui,Naila Kayani,Sara Sulaiman,Akbar S. Hussainy,Sajid H. Shah,Suhail Muzaffar ( Faculty of Health Sciences,
More informationBreast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status
ONCOLOGY REPORTS 19: 617-625, 2008 617 Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status BONG KYUNG SHIN 1,3, YOUNGSEOK LEE 1,3, JUNG BOK LEE
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More information